Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/14/2024 | $18.00 → $6.00 | Buy → Neutral | H.C. Wainwright |
7/8/2024 | $13.00 | Equal Weight → Overweight | Wells Fargo |
12/13/2023 | $11.00 | Equal Weight | Wells Fargo |
12/8/2023 | $8.00 | Neutral | Citigroup |
9/13/2023 | $19.00 | Overweight → Equal-Weight | Morgan Stanley |
9/5/2023 | $44.00 | Buy | H.C. Wainwright |
5/30/2023 | Overweight | Morgan Stanley | |
5/30/2023 | $31.00 | Buy | Jefferies |
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025 Cash, cash equivalents, and short-term marketable securities at September 30, 2024 of $562.4 million projected to provide cash runway to mid-2027 Company to hold webcast and conference call at 4:30pm ET today LOS ANGELES, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the dev
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. (NASDAQ:SLRN) is focused on providing patients life-changing new treatment options by i
Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in first quarter of 2025 LOS ANGELES, Oct. 16, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the formation of a scientific and patient advisory board comprised of leading experts and advocates in thyroid eye disease (TED). This group of advisors will provide important strategic input, clinical expertise and patient perspectives as ACELYRIN prepares t
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava
Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.
LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
Wells Fargo analyst Derek Archila upgrades Acelyrin (NASDAQ:SLRN) from Equal-Weight to Overweight and maintains the price target from $13 to $13.
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
4 - ACELYRIN, Inc. (0001962918) (Issuer)
S-3 - ACELYRIN, Inc. (0001962918) (Filer)
8-K - ACELYRIN, Inc. (0001962918) (Filer)
8-K - ACELYRIN, Inc. (0001962918) (Filer)
SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)
SC 13G - ACELYRIN, Inc. (0001962918) (Subject)
H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously
Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00
Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024 Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease (TED) expected in Q1 2025 Cash, cash equivalents, and short-term marketable securities at September 30, 2024 of $562.4 million projected to provide cash runway to mid-2027 Company to hold webcast and conference call at 4:30pm ET today LOS ANGELES, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the dev
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates. A live webcast of the conference call will be available on the Company's website under Events & Presentations. A replay of the webcast will be available on the Company's website for 90 days. About ACELYRINACELYRIN, INC. (NASDAQ:SLRN) is focused on providing patients life-changing new treatment options by i
Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint of HiSCR75 at 12 weeks Company to prioritize development of lonigutamab; dose confirmation ongoing in Phase 2 trial with plans to initiate Phase 3 program in Q1 2025 Cash, cash equivalents, and short-term marketable securities at June 30, 2024 of $635.2 million; projected to extend cash runway to mid-2027 Company to hold webcast and conference call at 5:00pm ET today LOS ANGELES, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that the Phase 3 tria